PubMed Trending Research Digest — October 01, 2026

Automated digest · 100 articles · 15 research areas · October 01, 2026

Overview

This week’s digest is dominated by two converging trends: (1) precision targeting—using biomarkers, spatial immune architecture, and mechanism-based drug design to improve outcomes in cancer and immune-mediated disease—and (2) systems-level biology—linking metabolism, microbiomes, and immune signaling to disease initiation, progression, and treatment response.

Across oncology, multiple studies emphasize how the tumor microenvironment and metastatic routes can be mapped and manipulated. Work on dural metastasis highlights meningeal lymphatic dysfunction and osteoclast interception as mechanistic drivers, while spatial profiling in bladder cancer identifies CXCL13-associated tertiary-lymphoid-structure–like niches as prognostic. In triple-negative breast cancer, temporal multi-omics yields a progression-free survival–based transcriptomic risk signature that may better guide chemo-immunotherapy decisions than single markers. Complementing these, cachexia research defines a spatial tumor–immune–stromal circuit (SEMA4A+ tumor cells, AQP9+ macrophages, LOXL2+ fibroblasts) that could become a targetable axis to prevent treatment-limiting weight loss.

In parallel, several papers advance “mechanism-first” therapeutics and diagnostics beyond traditional endpoints. In metabolic disease, new and next-generation incretin-based therapies (e.g., orforglipron, retatrutide, safiglipron, petrelintide, and retatrutide in type 2 diabetes) are tested for cardiovascular safety, obesity outcomes, and tolerability, while reviews synthesize GI adverse-effect patterns and lean-mass implications. In neurodegeneration, CSF α-synuclein seed amplification improves discrimination of Parkinson’s status in LRRK2 carriers, and multiple studies connect α-synuclein to lipid/mitochondrial dysfunction and vascular pro-atherogenic effects. Finally, microbiome and immune crosstalk appears repeatedly—from microbial degradation of metformin via AdhE to indole→AHR signaling in dendritic cells modulating ischemic stroke severity—reinforcing the idea that host-microbe interactions are actionable levers for both efficacy and risk reduction.

---

Cancer metastasis, tumor microenvironment, and immunotherapy

Osteoclasts intercept meningeal lymphatic paths for dural metastasis.

This study investigated how meningeal lymphatic dysfunction contributes to dural metastasis (DM) using a newly developed mouse DM model and clinical imaging patterns in cancer patients. Tumor progression impaired meningeal lymphatic drainage, and osteoclasts were found to intercept meningeal lymphatic paths to facilitate dural metastatic spread. These findings identify meningeal lymphatic dysfunction as a mechanistic driver of DM and suggest lymphatic/osteoclast-targeted strategies could improve outcomes for patients with advanced breast and lung cancers.

Zeng R, Zhao J, Peng H et al. · Nature · (2026) · View on PubMed ↗

Oncogenic viral infection triggers LAMP2A SUMOylation and chaperone-mediated autophagy to promote tumorigenesis.

This study investigated how oncogenic viral infection regulates chaperone-mediated autophagy (CMA) in the context of Kaposi’s sarcoma-associated herpesvirus, focusing on lysosomal LAMP2A post-translational modification. The authors found that TRIM32 drives SUMO2/3 conjugation of LAMP2A at K104, K132, and K289, promoting nuclear localization of SUMOylated LAMP2A and thereby enhancing CMA to support tumorigenesis. These findings identify a TRIM32–LAMP2A SUMOylation axis as a mechanistic target for limiting virus-driven cancer progression and for modulating CMA in malignancy.

Zhang Y, Dong Z, Chen X et al. · Nature microbiology · (2026) · View on PubMed ↗

Spatial evolution of a cachexia-promoting microenvironment in pancreatic cancer.

The study integrated single-cell RNA sequencing, Xenium spatial transcriptomics, multiplex immunohistochemistry, bulk transcriptomics, and functional experiments across human non-cachexia, pre-cachexia, and cachexia pancreatic cancer samples plus mouse models. It defined a cachexia-promoting niche composed of SEMA4A+ tumor cells, AQP9+ macrophages, and LOXL2+ cancer-associated fibroblasts, with SEMA4A-associated signaling promoting BMP2-dependent acquisition of an AQP9-associated macrophage program. This is significant because it maps a spatially organized tumor–immune–stromal circuit that could be targeted to prevent or treat cancer cachexia.

Hu Y, Lv G, Yuan H et al. · Cell · (2026) · View on PubMed ↗ · Free PDF ↗

AARS2-SIRT5-Driven DLD K445 Lactylation Promotes Cuproptosis Resistance in Glioblastoma Stem Cells.

This study investigated how an AARS2–SIRT5–driven lactylation pathway regulates dihydrolipoamide dehydrogenase (DLD) K445 lactylation to promote cuproptosis resistance in glioblastoma stem cells (GSCs). It found that lactate-dependent AARS2 catalyzes DLD K445 lactylation while SIRT5 reverses the modification via NAD+-dependent delactylation, and that DLD K445 lactylation supports resistance to cuproptosis. These mechanistic insights are important because they identify a potential vulnerability in therapy-resistant GSCs by targeting the lactylation control of cuproptosis.

Ding M, Xu H, Liu C et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · (2026) · View on PubMed ↗ · Free PDF ↗

---

Cancer diagnostics and imaging biomarkers

A multi-omics analysis of advanced triple-negative breast cancer identifies predictors to chemo-immunotherapy and on-treatment dynamics.

This study performed multi-omics profiling to identify predictors and on-treatment dynamics for chemo-immunotherapy in advanced triple-negative breast cancer (TNBC) using temporal data from the SYNERGY trial and EORTC-1553-SPECTA initiative. A transcriptomic progression-free survival (PFS)-based risk signature stratified outcomes and was validated across ICI-treated cohorts. The clinical significance is that it proposes a more actionable biomarker framework beyond PD-L1 and clarifies how TNBC microenvironments evolve during treatment.

Van Renne N, Agostinetto E, Joaquín García A et al. · Cell reports. Medicine · (2026) · View on PubMed ↗ · Free PDF ↗

Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients Presenting With Locally Advanced Breast Cancer.

This prospective study evaluated the false-negative rate (FNR) of sentinel lymph node biopsy (SLNB) after neoadjuvant chemotherapy (NAC) in patients with locally advanced breast cancer who achieved nodal complete response (cN0) on imaging. Using dual-tracer mapping (without nodal clipping) and completion axillary lymph node dissection, the study quantified SLNB FNR in this post-NAC setting. The results are clinically important for determining whether SLNB can safely replace full axillary dissection in selected patients after NAC.

Barrio AV, Mautner S, Capko D et al. · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · (2026) · View on PubMed ↗

Urine Methylation Test for Urothelial Cancer Diagnosis and Surveillance.

The study developed and validated a prospective, blinded, multicenter urine methylation test for urothelial cancer (UC) diagnosis and postoperative surveillance targeting methylation of AL021918.2 and vimentin (VIM). The key finding is that the urine methylation assay can distinguish UC from benign urinary and nonurothelial malignant conditions and can be used for postoperative surveillance, as evaluated across training and validation cohorts in China. This is clinically significant because it offers a noninvasive molecular test to improve early detection and recurrence monitoring in UC.

Wu Y, Han W, Xiong S et al. · JAMA network open · (2026) · View on PubMed ↗ · Free PDF ↗

Diagnostic Accuracy of Bosniak v2019 for Predicting Cancer and Unfavorable Histology in Class III-IV Cystic Renal Masses.

This retrospective multicenter study evaluated whether Bosniak v2019 and nodule size predict cancer and unfavorable histology in Bosniak III–IV cystic renal masses using pretreatment CT or MRI reviewed independently by radiologists across 10 institutions (2007–2024). The key finding was the diagnostic accuracy of Bosniak v2019 (and the added value of nodule size) for predicting malignancy and adverse histologic features based on surgical histopathology reference standards. This is significant because it can refine imaging-based risk stratification and guide management decisions for patients with complex cystic renal lesions.

Tse JR, Khalatbari S, Yosef M et al. · Radiology · (2026) · View on PubMed ↗

Multiplex Immunofluorescence-defined CXCL13-associated TLS-like Niches Predict Outcome in Bladder Cancer.

This translational study analyzed 469 clinically annotated bladder cancer tumors using 41-plex multiplex immunofluorescence on the PhenoCycler platform to define CXCL13-associated tertiary lymphoid structure (TLS)-like niches. The key finding was that multiplex immunofluorescence-defined CXCL13-associated TLS-like niches (mTLS) predict patient outcome, and that mTLS-associated immune programs were characterized using bulk RNA-seq, CIBERSORTx deconvolution, Cox modeling, and spatial neighborhood analysis, with validation in orthotopic mouse models treated with an unspecified therapy (truncated). Scientifically and clinically, it supports using spatial immune architecture—beyond single markers like CXCL13—as a prognostic biomarker and potential guide for immunotherapy strategies in bladder cancer.

Maenosono R, Nishimura K, Tsujino T et al. · Clinical cancer research : an official journal of the American Association for Cancer Research · (2026) · View on PubMed ↗

Peripheral Blood as the Sole Source for Cancer Neoantigen and Reactive T-Cell Discovery.

This study proposed and evaluated a peripheral-blood-only workflow to discover cancer neoantigens and reactive T cells without tumor biopsy, using cell-free DNA whole-exome sequencing and T-cell isolation based on PD-1 and CD39 co-expression. In an initial cohort of eight metastatic cancer patients, the approach identified most neoantigens and increased the number of T-cell reactivities compared with standard biopsy-based techniques, while also uncovering additional neoantigens missed by tumor biopsy. Scientifically and clinically, this could broaden access to neoantigen-targeted T-cell therapies by reducing reliance on invasive tumor sampling and better capturing tumor heterogeneity.

Garcia-Garijo A, Creus-González I, Levy PL et al. · Cancer discovery · (2026) · View on PubMed ↗ · Free PDF ↗

---

Cancer therapeutics (drug trials, sequencing, and comparative effectiveness)

Giredestrant plus Everolimus in Advanced Breast Cancer.

This phase 3 open-label randomized trial evaluated giredestrant plus everolimus versus standard therapy in patients with ER-positive, HER2-negative locally advanced or metastatic breast cancer that progressed after CDK4/6 inhibitor plus endocrine therapy. The combination targeted the estrogen receptor (giredestrant) and the PI3K–AKT–mTOR pathway (everolimus) to overcome endocrine-therapy resistance. The study’s clinical significance lies in providing an evidence-based strategy for patients with advanced, treatment-resistant hormone receptor–positive breast cancer.

Mayer EL, Tolaney SM, Martín M et al. · The New England journal of medicine · (2026) · View on PubMed ↗

Quality of life in first-line trials for endometrial cancer: A systematic review.

This systematic review evaluated quality of life (QoL) outcomes from phase II–III randomized trials in advanced or recurrent endometrial cancer that reported patient-reported outcomes using validated instruments. The key finding was a synthesis of how QoL/PRO results were measured and reported across pivotal first-line trials that shaped current clinical practice. This is clinically significant because it clarifies the evidence base for patient-centered outcomes when comparing therapeutic strategies in endometrial cancer.

Tuninetti V, Farolfi A, Butticè S et al. · Tumori · (2026) · View on PubMed ↗ · Free PDF ↗

Werner helicase inhibitor for advanced microsatellite instability solid tumors: a phase 1 trial.

In this first-in-human phase 1 trial, RO7589831 (VVD-133214), a covalent Werner syndrome helicase (WRN) inhibitor, was evaluated in 88 patients with advanced solid tumors that were microsatellite instability (MSI) and/or mismatch repair deficient. The study assessed safety/tolerability and determined a recommended phase 2 dose and schedule, alongside antitumor activity endpoints such as disease control rate. By targeting WRN as a synthetic lethal vulnerability in MSI/dMMR cancers, RO7589831 provides early clinical validation for helicase inhibition as a precision oncology approach.

Yap TA, Fontana E, Cook N et al. · Nature medicine · (2026) · 1 citations · View on PubMed ↗ · Free PDF ↗

Final results and predictive biomarkers of response and long-term outcomes with first-line pembrolizumab monotherapy in advanced renal cell carcinoma in the phase II KEYNOTE-427 study.

This analysis reported final efficacy, safety, and exploratory predictive biomarkers for first-line pembrolizumab monotherapy in advanced renal cell carcinoma from the phase II KEYNOTE-427 study. In treatment-naïve patients with advanced clear cell RCC (cohort A) and non-clear cell RCC (cohort B), the study evaluated objective response rate and long-term outcomes and linked response to candidate biomarkers (details truncated). These results refine how pembrolizumab performs across RCC subtypes and which biomarkers may help predict durable benefit.

McDermott DF, Signoretti S, Lee JL et al. · Annals of oncology : official journal of the European Society for Medical Oncology · (2026) · View on PubMed ↗

Upadacitinib Is Associated with the Lowest Risk of Treatment Failure Among Advanced Therapies for Ulcerative Colitis: A Real-World Administrative Claims Study.

This real-world administrative claims study compared advanced therapy effectiveness in ulcerative colitis (UC) patients using OptumLabs data, focusing on time to treatment failure among biologics and small molecules including upadacitinib. Among patients initiating infliximab, adalimumab, vedolizumab, ustekinumab, tofacitinib, or upadacitinib (2016–2023), upadacitinib showed the lowest risk of treatment failure based on a composite endpoint of hospitalization, surgery, or new corticosteroid prescription after >90 days (truncated). The findings support comparative effectiveness evidence for treatment selection in UC outside clinical trials.

Hupé M, Ahuja D, Yeh KH et al. · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · (2026) · View on PubMed ↗

Tucatinib, trastuzumab, and capecitabine as second- or third-line therapy after trastuzumab deruxtecan in HER2-positive metastatic breast cancer: A multicenter retrospective study in France.

This multicenter retrospective French study evaluated the effectiveness of the combination tucatinib, trastuzumab, and capecitabine (TTC) as second- or third-line therapy in patients with HER2-positive metastatic breast cancer after progression on trastuzumab deruxtecan (T-DXd). TTC produced clinically meaningful outcomes in this post–T-DXd setting, addressing an evidence gap for optimal subsequent treatment strategies. The study supports TTC as a potential therapeutic option after T-DXd failure and helps guide sequencing in HER2-positive metastatic breast cancer.

Frenel J, de Nonnevile A, Guerin-Charbonnel C et al. · Breast (Edinburgh, Scotland) · (2026) · View on PubMed ↗ · Free PDF ↗

Atezolizumab Plus Bevacizumab Treatment for Patients With Hepatocellular Carcinoma in the Barcelona Clinic Liver Cancer B2 Stage.

This retrospective study analyzed 113 patients with Barcelona Clinic Liver Cancer (BCLC) stage B2 hepatocellular carcinoma to identify treatment approaches associated with survival beyond that predicted by an established prognostic model. The key finding was that certain systemic or combined treatment modalities (beyond transarterial chemoembolization alone) were associated with survival outcomes exceeding model-predicted expectations in this intermediate-stage subgroup. These results may help refine real-world treatment selection for BCLC-B2 patients where standard transarterial chemoembolization has limited efficacy.

Ouchi K, Ninomiya M, Tsuruoka M et al. · Journal of gastroenterology and hepatology · (2026) · View on PubMed ↗ · Free PDF ↗

---

Gene editing and advanced cellular therapies

Prime editing of human hematopoietic stem cells for correction of GATA2 deficiency.

This Science Translational Medicine study developed and tested prime editing to correct GATA2 deficiency by editing patient-derived CD34+ hematopoietic stem and progenitor cells (HSPCs) ex vivo. Prime editing corrected a GATA2 pathogenic variant with improved safety characteristics, emphasizing reduced off-target effects and genotoxicity compared with nuclease-dependent approaches. The work is significant because it advances a potentially curative, safer gene-editing strategy for GATA2-deficient immunodeficiency.

Wolff JH, Skov TW, Dorset SR et al. · Science translational medicine · (2026) · View on PubMed ↗

Co-expression of non-signaling CARs enhances EGFRvIII-specific CAR T-cell cytotoxicity against head and neck squamous cell carcinoma.

This study engineered CAR T cells targeting EGFRvIII for head and neck squamous cell carcinoma (HNSCC) and tested whether co-expression of non-signaling CARs improves EGFRvIII-specific cytotoxicity. Co-expression of non-signaling CARs enhanced EGFRvIII CAR T-cell killing despite heterogeneous EGFRvIII expression and the constraints of the tumor microenvironment. The work supports a CAR design strategy to improve efficacy against antigen-variable tumors while leveraging EGFRvIII as a tumor-associated target.

Grueter K, Sander N, Coen L et al. · BMC cancer · (2026) · View on PubMed ↗ · Free PDF ↗

Spatially confined IL-12 programs CAR-NK through mTORC1 to coordinate antitumor immune networks.

This study engineered a spatially confined IL-12–programmed CAR-NK cell platform to enhance antitumor immunity while coordinating tumor immune networks. IL-12 signaling converged on mTORC1 via Ras-ERK and PI3K pathways to sustain metabolic fitness, autonomous expansion, and effector function, and it also activated bystander NK cells, T cells, and macrophages to remodel the tumor microenvironment. The approach provides a mechanistic strategy to improve CAR-NK efficacy by localizing IL-12 program activity to reduce systemic toxicity concerns.

Tarannum M, Dinh K, Stanojevic M et al. · Cancer discovery · (2026) · View on PubMed ↗

---

Infectious disease (including vaccines and antimicrobial strategies)

Amikacin Liposome Inhalation Suspension in Newly Diagnosed Mycobacterium avium Complex Lung Disease: A Phase 3b, Double-blind, Randomized Clinical Trial (ENCORE).

This phase 3b, double-blind, randomized clinical trial (ENCORE) tested amikacin liposome inhalation suspension (ALIS) plus guideline-based multidrug therapy (azithromycin and ethambutol) versus placebo plus multidrug therapy in adults newly diagnosed with Mycobacterium avium complex lung disease (MACLD). The trial evaluated whether adding ALIS improved efficacy and maintained safety in patients who had not yet started antibiotics. The results are clinically important because they address whether ALIS can improve outcomes when used upfront rather than only for refractory MACLD.

Daley CL, Morimoto K, Thomson R et al. · American journal of respiratory and critical care medicine · (2026) · View on PubMed ↗

Oropouche virus causes severe congenital disease in embryonic mice.

This study examined Oropouche virus (OROV) pathogenesis in embryonic Swiss mice by injecting a low inoculum of the epidemic OROVIRCCS-SCDC_1/2024 strain into the placenta. OROV replicated across embryonic organs, especially the brain, causing multi-organ pathology including pneumonitis, myocarditis, steatohepatitis, and severe neuropathology with microcephaly, ventriculomegaly, and neural cell loss. The results provide strong preclinical evidence that OROV can cause severe congenital disease via vertical transmission, informing risk assessment and future interventions for pregnancy.

Darmuzey M, Verdijk RM, Ferrié M et al. · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗

Meta-analysis of Maternal and Fetal Outcomes of Crimean-Congo Hemorrhagic Fever during Pregnancy.

This meta-analysis studied maternal and fetal outcomes of Crimean-Congo hemorrhagic fever (CCHF) during pregnancy using harmonized patient-level data from published and unpublished cases. Across 55 pregnancies, maternal mortality was 28.8% and fetal loss was 57.4%, with maternal mortality increasing by gestational age and fetal loss peaking in the third trimester (85.7% in the truncated results). Clinically, these quantified risks support improved counseling, surveillance, and prioritization of therapeutic strategies for pregnant patients with CCHF.

Donk B, Güllü D, Cırık AM et al. · Emerging infectious diseases · (2026) · View on PubMed ↗ · Free PDF ↗

Complexome profiling of mitochondria in the myzozoan parasite of oysters, Perkinsus marinus.

The study used complexome profiling proteomics to characterize mitochondrial electron transport chain (mETC), F1Fo-ATP synthase, mitochondrial ribosome, and TOM complex composition in the myzozoan oyster parasite Perkinsus marinus. The key finding is that mitochondrial complex composition in this lineage can be mapped and compared, revealing lineage-specific diversity in mitochondrial complex architecture beyond what is known from other unicellular eukaryotes. This advances understanding of how divergent mitochondrial complexes support parasite bioenergetics and survival, providing targets for future functional studies.

Maclean AE, Iorillo O, Faktorová D et al. · PLoS pathogens · (2026) · View on PubMed ↗ · Free PDF ↗

Duration of antibiotic therapy in sepsis and severe infections in critically ill patients.

The study reviewed and synthesized evidence on how to determine antibiotic duration in sepsis and severe infections in critically ill patients, integrating microbiology and pharmacokinetic/pharmacodynamic (PK/PD) considerations. The key finding is that optimal duration is difficult to define universally because bacterial clearance depends on factors such as inoculum size, biofilms, mutant selection windows, altered drug distribution in critical illness, and infection-site/source control. This is significant for guiding more individualized antibiotic stewardship strategies that balance cure, resistance prevention, and minimization of microbiome and superinfection risks.

Timsit JF, Roberts JA, Kanj S et al. · American journal of respiratory and critical care medicine · (2026) · View on PubMed ↗

mRNA-based seasonal influenza vaccines: an overview of immunogenicity, efficacy, and safety.

This overview summarized clinical evidence on immunogenicity, efficacy, and safety of mRNA-based seasonal influenza vaccines, focusing on platforms such as Moderna’s mRNA-1010 and Pfizer’s modified-nucleoside RNA (modRNA), plus combination approaches including Moderna’s mRNA-1083. It reports that iterative mRNA platform optimization supports robust immune responses with acceptable safety across trial settings. The synthesis is relevant for informing vaccine development and clinical expectations as mRNA influenza vaccines expand beyond egg-based formulations.

Domnich A, Orsi A · Frontiers in immunology · (2026) · View on PubMed ↗ · Free PDF ↗

Decoupling reactogenicity from efficacy enables safer mRNA vaccines, AAV gene delivery, and in vivo base editing.

This mechanistic study examined whether acute innate reactogenicity can be separated from efficacy for nucleic-acid therapeutics, testing mRNA lipid nanoparticle (LNP) vaccines, adenoviral vectors, and AAV9 gene delivery, as well as in vivo base editing. The authors identified a conserved early innate inflammatory program peaking around six hours after administration that is driven mainly by nucleic-acid cargo sensing rather than lipid components, and showed it is mechanistically separable from antigen expression, adaptive immune priming, and genome-editing efficacy. This decoupling provides a scientific framework for designing safer nucleic-acid therapies that enable higher or more targeted dosing.

Lainšček D, Malenšek Š, Forstnerič V et al. · Molecular therapy : the journal of the American Society of Gene Therapy · (2026) · View on PubMed ↗

---

Autoimmunity and immune-mediated diseases

A two-hit mechanism triggers autoimmune hair loss.

This study examined the initiation of autoimmune alopecia in the context of immune regulation and neural activation, focusing on transient regulatory T (Treg) cell depletion during the hair cycle in mice. Depleting Treg cells during anagen (but not telogen) triggered CD8+ T-cell–mediated destruction of immune-privileged hair follicle stem cells (HFSCs), and the effect depended on sympathetic nerve activity. The results define a two-hit mechanism linking immune dysregulation and sympathetic activation to tissue-specific autoimmunity, informing potential timing- and pathway-based interventions for autoimmune hair loss.

Cui J, Wu P, Chang Y et al. · Nature · (2026) · View on PubMed ↗

Low-Dose Oral Minoxidil Use for Pediatric Hair Disorders: An International Consensus Statement.

This international consensus study surveyed clinicians and reviewed literature to develop recommendations for low-dose oral minoxidil (LDOM) use in pediatric patients younger than 12 years with hair disorders. The key finding was that a modified Delphi process produced standardized guidance on patient selection, dosing, safety monitoring, and follow-up for LDOM in this age group. These consensus recommendations support safer off-label prescribing of minoxidil in children by clarifying who should receive LDOM and how to monitor adverse effects.

Akiska YM, Fu J, Castelo-Soccio L et al. · JAMA dermatology · (2026) · View on PubMed ↗

Fibro-Adipogenic Progenitor Ablation Triggers Muscle Atrophy Through Cell Death-Induced Inflammation.

This study used tamoxifen-inducible fibro-adipogenic progenitor (FAP)–specific diphtheria toxin ablation in PdgfraCre-ERT2/+;Rosa26^DTA/+ mice to test how PDGFRα+ FAP loss affects skeletal muscle mass and function in extensor digitorum longus (EDL) and soleus (SOL). FAP ablation triggered muscle atrophy through cell-death–induced inflammation. These findings mechanistically link PDGFRα+ FAP homeostasis to inflammatory pathways that drive sarcopenia-like muscle wasting and suggest FAP-targeted modulation as a potential therapeutic direction.

Luo YE, Lee YI, Abe-Teh Z et al. · Journal of cachexia, sarcopenia and muscle · (2026) · View on PubMed ↗ · Free PDF ↗

Fenfluramine in Rett syndrome: A multidimensional clinical study.

This prospective, open-label, single-center clinical study evaluated adjunctive fenfluramine in patients with classic Rett syndrome carrying pathogenic MECP2 variants. Fenfluramine was assessed for efficacy, safety, and tolerability over 3 and 6 months as part of a multidimensional treatment evaluation. If confirmed in larger controlled studies, targeting serotonergic and sigma-1 receptor pathways with fenfluramine could broaden symptomatic management for MECP2-related, drug-resistant epilepsy and comorbid Rett features.

Gonzalez-Alguacil E, Lamagrande Casanova N, Luján Bonete M et al. · Epilepsia open · (2026) · View on PubMed ↗ · Free PDF ↗

Autoantibody Profiles of Immune Checkpoint Inhibitor-Associated Myasthenia and Myositis.

This retrospective multicenter cohort study characterized autoantibody profiles in immune checkpoint inhibitor (ICI)-associated myasthenia and myositis in 50 Japanese patients. Using conventional autoantibody assays plus cytometric cell-based assays, RNA immunoprecipitation, and immunohistochemistry, the authors mapped serological spectra and assessed associations with severe clinical features. The work improves immunologic stratification of these rare but life-threatening adverse events, potentially guiding diagnosis and risk prediction in patients receiving ICIs.

Kawazoe T, Tezuka T, Ishizawa K et al. · Cancer control : journal of the Moffitt Cancer Center · (2026) · View on PubMed ↗ · Free PDF ↗

Effect of emollients on skin barrier function in patients with atopic dermatitis: a systematic review and meta-analysis.

This systematic review and meta-analysis synthesized randomized controlled trials to determine how emollients affect skin barrier function in patients with atopic dermatitis (AD), including whether benefits depend on duration of use. Across included human RCTs, emollients showed barrier-repair effects, but the evidence base did not establish definitive conclusions about the ideal usage duration. These findings support emollients as a core AD therapy while highlighting the need for better-designed trials to optimize treatment duration.

Yang Q, Zhang W · Acta dermatovenerologica Alpina, Pannonica, et Adriatica · (2026) · View on PubMed ↗

Targeting the Epigenetic-Immune Axis in Acute Myeloid Leukemia: Current Advances and Future Directions.

This review examined epigenetic dysregulation mechanisms in acute myeloid leukemia (AML) and how they intersect with immune evasion, focusing on DNA methylation, histone modifications, and chromatin remodeling as therapeutic targets. It highlights recent advances identifying multiple druggable epigenetic regulators (e.g., DNA methyltransferases and TET dioxygenases, histone methyltransferases and demethylases) and outlines emerging epigenetic- and immune-based treatment strategies. These findings support a rationale for combination epigenetic-immune therapies to restore differentiation and improve anti-leukemia immune responses in AML.

Ghosh D, Ayoub M, Karmakar S et al. · Current oncology reports · (2026) · View on PubMed ↗

Obsessive-Compulsive Disorder in Adulthood: Etiology, Diagnosis, and Treatment.

This narrative review summarized adult obsessive-compulsive disorder (OCD) etiology, diagnosis, and treatment, drawing on the revised German clinical practice guideline and relevant literature. It reports that genetic factors account for about 50% of variance with up to 30 associated loci identified, and it outlines roles for stressful/emotionally traumatic life events as psychological risk factors alongside current diagnostic and treatment recommendations. The significance is an updated, guideline-aligned synthesis to support evidence-based clinical decision-making for adult OCD management.

Voderholzer U, Jelinek L, Schennach R et al. · Deutsches Arzteblatt international · (2026) · View on PubMed ↗

Comparative efficacy, safety, and functional recovery of neonatal fc receptor inhibitors and conventional immunotherapies for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and network meta-analysis.

This systematic review and frequentist network meta-analysis compared neonatal Fc receptor (FcRn) inhibitors—efgartigimod alfa and rozanolixizumab—against conventional immunotherapies (e.g., IVIg/SCIg) for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) using randomized controlled trials. Across included RCTs, FcRn inhibitors were evaluated for relative efficacy, safety, and functional recovery outcomes versus standard treatments. The results are clinically significant because they synthesize comparative evidence to guide selection of targeted biologics for CIDP management.

Jiang Q, Gu Z · Frontiers in immunology · (2026) · View on PubMed ↗ · Free PDF ↗

Sublingual allergen immunotherapy: evidence from randomized trials, real-world studies and meta-analyses.

This narrative review synthesized evidence from randomized trials, real-world studies, and meta-analyses on sublingual allergen immunotherapy (SLIT) for IgE-mediated seasonal and perennial respiratory allergies across different allergen/product types and age groups. Overall, the review reports that SLIT has a favorable safety profile and demonstrates clinically meaningful efficacy with potential long-term disease-modifying effects. These conclusions are important for clinicians and patients deciding on SLIT as a disease-modifying option for respiratory allergic disease.

Paoletti G, Valli N, Di Bona D et al. · Frontiers in allergy · (2026) · View on PubMed ↗ · Free PDF ↗

Real-World Strategies for Biologic Dose Escalation and Reduction in Psoriasis and Psoriatic Arthritis: A Systematic Review.

This systematic review synthesized real-world evidence on biologic dose escalation and dose reduction strategies for moderate-to-severe psoriasis and psoriatic arthritis. The key finding was that real-world dosing adjustments occur frequently and are driven by response, safety, and practical considerations, but published data on definitions, criteria, and success rates are fragmented. Clinically, consolidating these patterns can guide more consistent decision-making when standard biologic regimens underperform or require optimization.

Crespi O, Giunipero di Corteranzo I, Bongiovanni E et al. · Journal of cutaneous medicine and surgery · (2026) · View on PubMed ↗

---

Neurodegeneration and neuroinflammation

Condensate-driven triglyceride reduction links α-synuclein to mitochondrial dysfunction.

This mechanistic study used lipidomic profiling in Caenorhabditis elegans to determine how α-synuclein (αSyn) inclusions affect lipid metabolism during aging. αSyn progressively reduced triacylglycerols, disrupted lipid droplet and mitochondrial structure, and these effects depended on αSyn’s lipid-binding and ability to condensate into inclusions. The findings link αSyn condensate-driven lipid dysregulation to mitochondrial dysfunction, strengthening a causal pathway relevant to Parkinson’s disease pathogenesis.

Zhang T, Herron-Bedoya A, Eugenia Goya M et al. · EMBO reports · (2026) · View on PubMed ↗ · Free PDF ↗

Mitochondrial membrane lipid cardiolipin controls fiber-type adaptations in aging muscle via estrogen-related receptor γ.

This study tested whether mitochondrial membrane cardiolipin causally controls skeletal muscle fiber-type adaptations during aging in mouse and human muscle. Using inducible, tissue-specific cardiolipin synthase 1 (Crls1) deletion to mimic age-related cardiolipin decline, the authors reproduced aging hallmarks including a shift from glycolytic to oxidative fibers, mediated via estrogen-related receptor γ. These results identify cardiolipin–ERRγ signaling as a mechanistic driver of age-associated mitochondrial and fiber remodeling, suggesting targets to preserve muscle metabolic health.

Finger F, Frost M, Watanabe S et al. · Nature aging · (2026) · View on PubMed ↗ · Free PDF ↗

Lysosomal dysfunction in neurodegenerative disease.

This narrative review synthesized genetic and mechanistic evidence implicating lysosomal dysfunction across neurodegenerative diseases. It highlights how impaired lysosomal degradation of misfolded proteins and endolysosomal trafficking contributes to neuronal dysfunction and cell loss. By consolidating lysosome-centered mechanisms, the review supports lysosomal pathways as actionable targets for developing disease-modifying therapies in neurodegeneration.

Brooker SM, Coukos R, Krainc D · Nature reviews. Neurology · (2026) · View on PubMed ↗

A single-center open-label, randomized, parallel-group controlled clinical trial on the long-term effect of the treatment with EGb 761 in blood markers of inflammation and neurodegeneration in patients with mild cognitive impairment: ACE-2020-EGb 761.

This single-center, open-label randomized controlled trial evaluated the long-term effects of EGb 761 (a standardized Ginkgo biloba extract) on plasma biomarkers of inflammation and neurodegeneration in 100 patients with mild cognitive impairment (MCI). After 12 months, participants receiving EGb 761 were assessed for changes in inflammatory/neurodegeneration-related proteins, cognitive performance, and core Alzheimer’s disease biomarkers, with results reported as final and extended outcomes (truncated). If EGb 761 favorably modulates these biomarkers, it would support a disease-modifying or neuroprotective role for this standardized extract in early cognitive decline.

Morato X, Marquié M, Tartari JP et al. · Journal of Alzheimer’s disease : JAD · (2026) · View on PubMed ↗

Cervical lymphadenectomy impairs brain lymphatic clearance and synaptic proteostasis.

The study examined how cervical lymphadenectomy affects brain health by combining retrospective analysis of cancer patients with mechanistic mouse and rat models that phenocopied abrupt disruption of meningeal lymphatic drainage. Impaired lymphatic clearance after bilateral cervical/submandibular node disruption was associated with cognitive impairment and neuroimaging changes, and the work implicated effects on cerebrospinal fluid flow and synaptic proteostasis. These findings are significant for surgical risk assessment and for understanding how lymphatic drainage supports synaptic maintenance.

Khan ZN, Clement CC, Roßmüller P et al. · Neuron · (2026) · View on PubMed ↗ · Free PDF ↗

H4K12 Lactylation Regulates NDUFS7 to Drive Microglia Reverse Electron Transport in Spinal Cord Injury.

This study investigated how histone H4 lysine 12 lactylation (H4K12la) regulates NDUFS7 to drive mitochondrial reverse electron transport (RET) and sustain microglial pro-inflammatory activation after spinal cord injury (SCI). It found that SCI increases lactate, leading to H4K12la-mediated upregulation of NDUFS7, which enhances mitochondrial activity and RET to trigger a ROS burst that enforces neuroinflammation. The work is significant because it links a specific lactylation-to-mitochondrial signaling axis to SCI secondary injury and identifies potential targets to modulate neuroinflammation.

Hong C, Jiang Z, Wu Z et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · (2026) · View on PubMed ↗ · Free PDF ↗

α-Synuclein Seeding Discriminates Between LRRK2 G2019S Variant Carriers with and Without Parkinson’s Disease.

This study assessed whether a cerebrospinal-fluid α-synuclein seed amplification assay (aSyn SAA) can discriminate Parkinson’s disease (PD) status among LRRK2 p.Gly2019Ser variant carriers and relate results to mitochondrial genetic burden. In a Norwegian cohort (76 LRRK2 G2019S carriers: 22 affected/54 unaffected; plus 714 idiopathic PD patients and 411 controls), α-synuclein seeding signals differentiated affected from unaffected LRRK2 G2019S carriers. The results suggest CSF aSyn SAA could serve as a pathology biomarker for LRRK2-related PD and help stratify risk in genetically defined populations.

Lüth T, Gabbert C, Kleinz T et al. · Movement disorders : official journal of the Movement Disorder Society · (2026) · View on PubMed ↗ · Free PDF ↗

---

Neuroimmune interfaces and brain immune niches

Hunger states modulate aggression via opposing dopamine pathways.

This study investigated neural mechanisms of hunger-driven aggression in Drosophila by identifying a “hangry neuron” in the mushroom body and testing dopaminergic modulation. Hunger states increased aggression intensity in a graded, nutrient-specific manner, and dopaminergic inputs bidirectionally modulated hangry neuron excitability through Dop1R1 (cAMP pathway) and Dop1R2 (calcium pathway). The work clarifies how dopamine receptor-specific signaling converts internal metabolic state into adaptive aggressive behavior, offering a tractable circuit-level model for motivational control.

Wang J, Lv Q, Gao Y et al. · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗

Constitutively active presynaptic release factor Unc13A prevents homeostatic sleep rebound in Drosophila.

The study used Drosophila genetics to express a constitutively active presynaptic release factor Unc13A mutant (Unc13AWRWR) to test mechanisms of homeostatic sleep rebound after sleep deprivation. Unc13AWRWR dominantly suppressed homeostatic rebound, producing near-complete elimination of recovery sleep while leaving baseline sleep largely normal. This provides mechanistic evidence that presynaptic release control via Munc13-family Unc13A can specifically gate sleep rebound circuitry.

Huang S, Fusca D, Moron V et al. · Current biology : CB · (2026) · View on PubMed ↗

Microglia with distinct origins and non-canonical phenotypes coexist within the border-like niche of the brain’s circumventricular organs.

This study used multi-omics to characterize immune cell origin and phenotype in the border-like niches of the brain’s circumventricular organs, specifically the area postrema (AP) and median eminence (ME), including microglia and macrophage compartments. CVO microglia displayed heterogeneous, ontogenically diverse phenotypes, including a CLEC7A^high myelin-associated subset in the ME shaped by ageing and metabolism, with fetal monocytes entering perinatally and generating long-lived populations. These results show that CVO microenvironments create distinct microglial programs with non-canonical phenotypes, informing how brain-border niches influence neuroimmune function.

Van Hove H, Bastos J, Kancheva D et al. · Immunity · (2026) · View on PubMed ↗ · Free PDF ↗

---

Cardiovascular disease and hemodynamics

Global, Regional, and National Burden of Heart Failure, 1990-2023: A Systematic Analysis for the Global Burden of Disease Study 2023.

This Global Burden of Disease Study 2023 analysis estimated the global, regional, and national burden of heart failure (HF) and its underlying etiologies across 204 countries and territories from 1990 to 2023. The key finding was that HF prevalence and etiologic contributions varied substantially by geography over time, enabling comparable population-level burden estimates. These results are clinically significant for prioritizing health-system planning and targeting prevention and treatment strategies to the dominant HF causes in each region.

Johnson CO, Abbasi M, Abbasifard M et al. · JAMA cardiology · (2026) · View on PubMed ↗

2026 AHA/ACC/ACS/ASNC/HRS/SCA/SCCT/SCMR/SVM Guideline for Perioperative Cardiovascular Management for Noncardiac Surgery: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

This guideline development report synthesized evidence to produce the 2026 AHA/ACC/ACS/ASNC/HRS/SCA/SCCT/SCMR/SVM guideline for perioperative cardiovascular management in adult patients undergoing noncardiac surgery. The key finding was the creation of updated, evidence-based recommendations for perioperative cardiovascular evaluation and management based on a comprehensive literature search from August 2022 to March 2023. This is clinically significant because it standardizes cardiovascular risk assessment and management steps to reduce perioperative complications in noncardiac surgical patients.

Thompson A, Fleischmann KE, Smilowitz NR et al. · Journal of the American College of Cardiology · (2026) · 1 citations · View on PubMed ↗

Disparities in pathways for anaemia care and recovery among women after major abdominal surgery: secondary analysis of a prospective cohort study in 29 countries.

This secondary analysis of a prospective cohort study across 427 hospitals in 29 countries examined disparities in anemia care and recovery among women after elective major abdominal surgery, using surgical pathway (gynaecology vs non-gynaecology) as a proxy exposure. It evaluated preoperative anemia prevalence, how anemia was recognized and managed across pathways and life stages, and associations with 30-day outcomes, estimating potential benefit from anemia correction. The study is significant for identifying where perioperative anemia management varies internationally and for informing targeted interventions to improve recovery in women.

Kamarajah SK, Hapangama D · BJS open · (2026) · View on PubMed ↗ · Free PDF ↗

Permissive Blood Pressure Targets in Pediatric Critical Care: The PRESSURE Randomized Clinical Trial.

This multicenter, unblinded pragmatic randomized clinical trial tested permissive mean arterial pressure (MAP) targets in hypotensive critically ill children receiving invasive ventilation and vasoactive drugs across 23 pediatric intensive care units in three countries. The study evaluated whether adopting a higher-permissive MAP strategy to reduce vasoactive drug exposure improves 30-day outcomes. If effective, the trial could change pediatric critical care hemodynamic targets to balance organ perfusion with medication exposure risk.

Inwald DP, Laing E, Broomhall JM et al. · JAMA · (2026) · View on PubMed ↗

---

Metabolic disease (obesity, diabetes, and cardiometabolic pharmacology)

Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial.

This phase 3, event-driven, randomized, open-label, non-inferiority trial (ACHIEVE-4) compared the cardiovascular safety of the oral non-peptide GLP-1 receptor agonist orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk. Orforglipron was evaluated for major adverse cardiovascular events (MACE) incidence against an active comparator to establish cardiovascular safety. The trial directly informs clinical use of non-peptide GLP-1 receptor agonists in high-risk type 2 diabetes populations.

Klein KR, Wysham C, Tuttle KR et al. · Lancet (London, England) · (2026) · View on PubMed ↗

Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity.

This phase 3 randomized, double-blind trial tested once-weekly subcutaneous retatrutide, a triple agonist of GIP, GLP-1, and glucagon receptors, versus placebo in adults with obesity without diabetes, including outcomes in participants with knee osteoarthritis and sleep apnea. Retatrutide produced substantial improvements in body weight and also assessed changes in WOMAC pain and apnea-hypopnea measures in relevant subgroups. These results support retatrutide’s potential as a multi-mechanism therapy for obesity with clinically meaningful effects on comorbid pain and sleep-disordered breathing.

Jastreboff AM, Kaplan LM, Davies MJ et al. · The New England journal of medicine · (2026) · View on PubMed ↗

Histologic Features and Clinical Outcomes of Lean Metabolic Dysfunction-Associated Steatotic Liver Disease.

This multinational retrospective observational study characterized lean metabolic dysfunction–associated steatotic liver disease (lean MASLD) using biopsy-confirmed cases from the Global MASLD project and evaluated noninvasive tests for advanced fibrosis. Lean MASLD showed distinct clinical and histologic features and was analyzed for prognostic outcomes compared with overweight/obese MASLD defined by BMI and waist circumference. The findings improve risk stratification and diagnostic performance for advanced fibrosis in patients who develop MASLD without obesity.

de Avila L, AlNaamani KM, Papatheodoridi M et al. · JAMA · (2026) · View on PubMed ↗

Food and Health: Nutrition for Prevention and Management of Cardiovascular Disease: 2026 ACC Scientific Statement: A Report of the American College of Cardiology.

This 2026 ACC Scientific Statement reviewed evidence on nutrition as a determinant of cardiovascular health and as part of prevention and management strategies for cardiovascular disease and related cardiometabolic conditions. The key finding was that contemporary guidance should shift from focusing on isolated nutrients to emphasizing whole foods and overall dietary patterns with attention to food choice and degree of processing. This is scientifically and clinically significant because it reframes dietary recommendations toward actionable patterns likely to reduce cardiovascular risk across multiple diseases.

Hu FB, Beleslin B, Blaha MJ et al. · Journal of the American College of Cardiology · (2026) · View on PubMed ↗

GHRH and GLP-1 receptor agonism promote human β-cell survival and improve glucose homeostasis in diabetic mice.

This preclinical study investigated whether growth hormone-releasing hormone receptor (GHRH-R) agonism using MR-409 alone or combined with the GLP-1 receptor agonist exendin-4 (Ex-4) promotes human β-cell survival and improves glucose homeostasis in diabetic mice and human islets. The key finding was that combined MR-409 and Ex-4 treatment enhanced β-cell survival and improved glucose homeostasis more effectively than either approach alone under diabetic conditions. This is scientifically significant because it supports a synergistic GHRH-R/GLP-1R strategy to preserve β-cell mass and function relevant to type 1 diabetes therapy.

Louzada RA, Gonzalez Medina M, Pita-Grisanti V et al. · Endocrinology · (2026) · View on PubMed ↗

Efficacy and Safety of Dual GLP-1/Glucagon Receptor Agonism in Overweight and Obesity: A Class-Specific Systematic Review and Meta-Analysis.

This class-specific systematic review and random-effects meta-analysis synthesized randomized controlled trials of dual GLP-1/glucagon receptor agonists—mazdutide, survodutide, cotadutide, and efinopegdutide—in adults with overweight or obesity. The analysis pooled efficacy and safety outcomes to estimate class-specific effects while avoiding conflation with GIP-containing agents (e.g., tirzepatide, retatrutide). Defining the distinct benefit–risk profile of dual GLP-1/GCGR agonism can guide evidence-based selection and development of next-generation anti-obesity therapies.

Amjad MM, Khan MM, Sarwar F et al. · Diabetes, obesity & metabolism · (2026) · View on PubMed ↗

Oral small-molecule GLP-1 receptor agonist safiglipron in early type 2 diabetes: a randomized, double-blind, placebo-controlled trial.

This phase 3, multicenter, randomized, double-blind, placebo-controlled trial (OUTSTAND-1) tested oral small-molecule GLP-1 receptor agonist safiglipron in 284 Chinese adults with early type 2 diabetes managed with diet and exercise. Safiglipron was evaluated over 32 weeks (with a 20-week active extension) for placebo-adjusted changes in HbA1c and related efficacy and safety outcomes across 30 mg, 60 mg, and 90 mg doses. If efficacy and tolerability are favorable, safiglipron could offer a convenient oral GLP-1 option for early T2D with potential benefits on glycemic control and weight-related outcomes.

Yu M, Peng L, Jiang C et al. · Nature medicine · (2026) · View on PubMed ↗ · Free PDF ↗

Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.

This phase 3 randomized, double-blind, placebo-controlled trial evaluated retatrutide (a GIP/GLP-1/glucagon receptor agonist) in adults with obesity and type 2 diabetes in the TRIUMPH-2 study. Retatrutide improved outcomes versus placebo (efficacy and safety assessed across multiple endpoints in a multi-country cohort of adults on stable type 2 diabetes therapy). The results are clinically significant because they test a multi-receptor incretin/glucagon strategy for treating both obesity and type 2 diabetes in a large real-world-like population.

Bellido V, le Roux CW, Ekinci EI et al. · Lancet (London, England) · (2026) · View on PubMed ↗

Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial.

This phase 2 randomized, double-blind, placebo-controlled trial tested once-weekly petrelintide, a long-acting human amylin analogue, in adults with obesity without type 2 diabetes (ZUPREME 1). Petrelintide was evaluated for efficacy and safety against placebo in a multicentre trial across Poland, Romania, and the USA. The study is significant because it targets amylin signaling as a mechanism distinct from incretin-based therapies for long-term weight management.

Garvey WT, Ard J, Connery L et al. · The lancet. Diabetes & endocrinology · (2026) · View on PubMed ↗

Targeting osteoblast fatty acid metabolism attenuates skeletal and cardiovascular complications in chronic kidney disease models.

The study investigated whether targeting osteoblast fatty acid metabolism can mitigate skeletal and cardiovascular complications in chronic kidney disease (CKD) models, identifying glycerol-3-phosphate acyltransferase 2 (GPAT2) as a key regulator. The key finding is that elevated osteoblast GPAT2 in mouse and human CKD diverts free fatty acids away from mitochondrial oxidation toward lysophosphatidic acid synthesis, increasing fibroblast growth factor 23 (FGF23) production and impairing phosphate incorporation into bone, whereas osteoblast-specific Gpat2 deletion restores osteo-mineralization and improves systemic phosphate balance. This is significant because it links a specific osteoblast metabolic enzyme (GPAT2) to CKD mineral and cardiovascular pathology and suggests a potential therapeutic target.

Simic P, Xie H, Zhou W et al. · The Journal of clinical investigation · (2026) · View on PubMed ↗ · Free PDF ↗

Gastrointestinal adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents.

This narrative expert review synthesized evidence from randomized trials, observational studies, meta-analyses, and pharmacovigilance to characterize gastrointestinal (GI) adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists across approved and late-stage pipeline therapies. It found that nausea, vomiting, diarrhea, and constipation are the most common GI limitations and discusses mechanistic contributors and clinical implications for discontinuation and tolerability. Clinically, the review supports more informed selection, counseling, and management strategies to improve adherence and outcomes in type 2 diabetes and obesity treatment.

Singhani V, Ehsan M, Valencia S et al. · Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition · (2026) · View on PubMed ↗ · Free PDF ↗

Exposure-Response Analyses of Ropeginterferon Alfa-2b in Essential Thrombocythemia.

This study analyzed population pharmacokinetics–pharmacodynamics and exposure–response relationships for ropeginterferon alfa-2b in patients with essential thrombocythemia (ET) using aggregated data from five clinical trials that included Asian and Caucasian patients and healthy volunteers. Sequential PopPK-PD modeling linked ropeginterferon alfa-2b exposure to hematologic marker changes, including platelet and white blood cell counts. These findings support more rational dosing of ropeginterferon alfa-2b in ET by quantifying how drug exposure translates into measurable disease-control effects.

Qin A, Masarova L, Chen H et al. · Journal of clinical pharmacology · (2026) · View on PubMed ↗ · Free PDF ↗

Beyond weight loss: a narrative review of tirzepatide’s impact on muscle and lean mass in people with overweight and obesity.

This narrative review evaluated evidence on how tirzepatide, a dual GIP/GLP-1 receptor agonist, affects lean mass and related body-composition measures in people with overweight and obesity, including studies with and without type 2 diabetes. Across ten included studies (randomized trials, observational studies, and modeling analyses), the review focused on whether weight loss from tirzepatide is accompanied by preservation or loss of muscle/lean mass. Clinically, clarifying lean-mass effects is important for optimizing tirzepatide’s long-term safety and functional outcomes during obesity treatment.

Wilkinson T, Ramzan R · Current medical research and opinion · (2026) · View on PubMed ↗ · Free PDF ↗

Potential bone marrow-driven reduction of circulating inflammatory monocytes by semaglutide in Type 2 diabetes.

This study investigated the cardiovascular–hematopoietic axis in 16 adults with type 2 diabetes receiving semaglutide to test whether GLP-1 receptor agonism reduces circulating inflammatory monocytes via bone-marrow–mediated mechanisms. The key finding was that semaglutide was associated with a reduction in circulating inflammatory monocytes consistent with a bone marrow-driven anti-inflammatory effect. Mechanistically, this supports a human pathway that may contribute to the cardiovascular benefits of semaglutide in type 2 diabetes.

Teunis CJ, Collins TJC, Oostveen RF et al. · European heart journal · (2026) · View on PubMed ↗ · Free PDF ↗

---

Microbiome and host-microbe interactions

Microbial aldehyde-alcohol dehydrogenase degrades metformin to limit therapeutic response in type 2 diabetes.

The study investigated whether gut microbes directly inactivate metformin by identifying a microbial aldehyde-alcohol dehydrogenase, AdhE, from Eubacterium species enriched in low metformin responders. AdhE degraded metformin into pharmacologically inactive products, reducing intestinal/systemic metformin exposure, and genetic deletion or phage-mediated depletion of AdhE-producing Eubacterium hallii MD1 restored metformin exposure and glycemic control in mice. This is clinically significant because it links a specific microbial gene (AdhE) to variable metformin efficacy and suggests microbiome-targeted strategies to improve response.

Zhao Y, Peng C, Xia Y et al. · Cell metabolism · (2026) · View on PubMed ↗ · Free PDF ↗

Gut microbiota primes stroke severity via the AHR in intestinal dendritic cells.

The study tested how gut microbiota influences ischemic stroke severity by focusing on indole-producing Escherichia coli and the aryl hydrocarbon receptor (AHR) pathway in intestinal dendritic cells (DCs) in mice and in patient data. Microbial indole triggered AHR-dependent responses in DCs, and DC-specific AHR deletion improved stroke outcomes while preserving intestinal conventional type 1 DCs. This is significant because it identifies a gut-immune signaling axis (indole→AHR in DCs) that could be therapeutically modulated to reduce stroke severity.

Delgado Jiménez R, Ruggles A, Adedokun MA et al. · Cell · (2026) · View on PubMed ↗ · Free PDF ↗

Microbiome signatures linked to cancer and treatment adverse events in a real-world cohort.

This real-world study analyzed gut microbiome signatures linked to cancer and adverse events using a mixed-cancer cohort from the Mayo Clinic Cancer Microbiome (1,364 cancer patients and 287 healthy controls). Using a framework to control for non-specific associations with cancer, comorbidities, and demographics, it identified cancer-associated microbial species across five cancer classes and assessed links to treatment adverse events. The scientific significance is that it provides more generalizable microbiome biomarkers for cancer biology and toxicity risk beyond single-cancer studies.

Yang L, Singh V, Gawey BJ et al. · Cell · (2026) · View on PubMed ↗

Intestinal lipid metabolism controls molecular and behavioral immunity through NHR-68 and gut-brain signaling in Caenorhabditis elegans.

The study examined how intestinal lipid metabolism regulates molecular and behavioral immunity in Caenorhabditis elegans, focusing on the nuclear hormone receptor NHR-68 (and its relationship with NHR-10) and polyunsaturated fatty acid (PUFA) homeostasis. The key finding is that NHR-68 controls linoleic acid (LA) homeostasis and that loss of NHR-68 disrupts pathogen avoidance behavior, while LA supplementation restores avoidance and fat-3 inhibition (increasing LA) enhances avoidance whereas fat-2 inhibition (reducing LA synthesis) diminishes it. This links specific gut lipid metabolic pathways to neural immune control via NHR-68, highlighting a conserved gut-brain immunometabolic axis with potential relevance to host defense regulation.

Ren J, Sang Y, Kim YM et al. · PLoS biology · (2026) · View on PubMed ↗ · Free PDF ↗

---

Inflammation, thrombosis, and vascular biology

Global, regional, and national burden of exposure to chewing tobacco, 1990-2023: a systematic analysis of the Global Burden of Disease Study 2023.

This systematic analysis quantified global, regional, and national exposure to chewing tobacco and the attributable health burden from 1990 to 2023 using Global Burden of Disease Study 2023 estimates for adults aged 15 years and older across 204 countries and territories. Chewing tobacco exposure and its health impacts were tracked separately from other smokeless tobacco products to inform trends and policy needs. The findings provide actionable surveillance metrics for tobacco control by clarifying the evolving burden attributable specifically to chewing tobacco.

The Lancet. Global health · (2027) · View on PubMed ↗

Hospital Indicators for the Management of Native and Prosthetic Valve Infective Endocarditis Across Brazilian Regions From 2015 to 2024.

This retrospective ecological time-series study analyzed Brazilian Unified Health System Hospital Information System data (DATASUS) from 2015 to 2024 to examine hospital indicators for native-valve and prosthetic-valve infective endocarditis across regions. The key finding was characterization of regional distributions and temporal trends in approved hospital admissions, in-hospital deaths, death proportions, and length of stay for these valve infection types. These findings are significant for health-system benchmarking and for identifying where care processes or outcomes may need improvement.

Marques LL, Akerman LKC, Diniz LM et al. · Cureus · (2026) · View on PubMed ↗ · Free PDF ↗

Endotheliopathy and VWF-ADAMTS13 axis dysfunction in VEXAS thrombogenicity.

This cohort study investigated endotheliopathy and the VWF–ADAMTS13 axis in VEXAS syndrome thrombogenicity in 40 NIH-referred patients with defined UBA1 somatic variants. VEXAS patients had increased plasma VWF and FVIII activity compared with age-matched controls, consistent with endothelial activation contributing to hypercoagulability. These mechanistic insights suggest that the VWF–ADAMTS13/endothelial pathway may be a therapeutic target to reduce thrombosis risk in VEXAS.

Hulshof AM, Groarke EM, Schneppenheim S et al. · Blood · (2026) · View on PubMed ↗ · Free PDF ↗

The Iron Chaperone PCBP2 Controls Systemic Iron Homeostasis by Regulating Iron Flux in Red Pulp Macrophages.

This study examined how the iron chaperone PCBP2 regulates systemic iron homeostasis by controlling iron flux in red pulp macrophages, using mouse models with macrophage-specific PCBP2 loss and analyses of human macrophages. PCBP2 expression increased with iron deficiency, and mice lacking PCBP2 in macrophages developed iron-restricted erythropoiesis (including reduced bone marrow iron and suppressed hepcidin) while accumulating iron in the spleen. The findings identify PCBP2 as a key regulator of macrophage iron redistribution, advancing understanding of iron disorders and potential intervention points.

Grander M, Mueller L, Trebo M et al. · Blood · (2026) · View on PubMed ↗

Identification of Secreted Modular Calcium-Binding Protein 1 as a Novel Endogenous Protective Molecule Against Acute Myocardial Infarction-Induced Cardiac Rupture.

This study investigated secreted modular calcium-binding protein 1 (SMOC1) as an endogenous protective factor against acute myocardial infarction (AMI)-induced cardiac rupture using plasma and left-ventricular tissue from AMI patients and AMI mice, with unbiased proteomics plus loss- and gain-of-function animal models. SMOC1 was identified as a key altered secreted protein and its modulation changed susceptibility to cardiac rupture after AMI. These findings suggest SMOC1 could be a novel mechanistic target and potential therapeutic candidate to prevent the fatal complication of cardiac rupture following AMI.

Gong W, Li S, Zhang Z et al. · Circulation · (2026) · View on PubMed ↗

α-Synuclein Promotes Atherosclerosis by Impairing Macrophage Autophagic Flux.

This study evaluated whether circulating α-synuclein (α-Syn) promotes atherosclerosis by impairing macrophage autophagic flux, linking observations in humans and mouse models. The key finding was that α-Syn was detected in human atherosclerotic plaques and that genetic deletion of α-Syn reduced atherosclerotic lesion size and macrophage lipid accumulation in a mouse atherosclerosis model. These results implicate α-Syn as a vascular pro-atherogenic factor and suggest autophagy modulation in macrophages as a potential therapeutic target.

Qin M, Xiang X, Guo X et al. · Aging cell · (2026) · View on PubMed ↗ · Free PDF ↗

---

Liver, gastrointestinal, and hepatobiliary disease

Hypothermic oxygenated and normothermic machine perfusion mitigate innate systemic and hepatic inflammation after liver transplantation.

This mechanistic substudy of the HOPE-NMP randomized controlled trial investigated immune responses after liver transplantation in recipients of extended-criteria donor livers randomized to static cold storage (SCS), end-ischaemic hypothermic oxygenated perfusion (HOPE), or end-ischaemic normothermic machine perfusion (NMP). HOPE and NMP reduced innate systemic and hepatic inflammation compared with SCS, indicating immunomodulatory benefits of these preservation strategies in humans. The findings strengthen the translational rationale for HOPE/NMP to mitigate ischaemia-reperfusion injury and improve post-transplant outcomes.

Lurje I, Horn P, Guillot A et al. · Gut · (2026) · View on PubMed ↗ · Free PDF ↗

Risk-Stratified Surveillance for Recurrent Hepatocellular Carcinoma After Liver Transplantation: A Comparison With the RETREAT-Guided Surveillance Protocol.

This single-center retrospective study compared adherence to and effectiveness of a risk-stratified surveillance protocol for hepatocellular carcinoma (HCC) recurrence after liver transplantation (LT) against the RETREAT-guided surveillance protocol. The key finding was the relative performance of the explant-pathology–based low- vs high-risk surveillance strategy (using AJCC tumor stage, grade, and vascular invasion) across multiple cutoffs, assessing protocol adherence and outcomes (results truncated). Clinically, it aims to optimize post-LT surveillance intensity to detect recurrence effectively while aligning follow-up with recurrence risk.

Dharia IP, Leven EA, Schmidt N et al. · Clinical transplantation · (2026) · View on PubMed ↗

Endoscopic Ultrasound-Guided Hepaticogastrostomy With Plastic Stent Versus Metallic Stent for Malignant Biliary Obstruction: A Meta-Analysis.

This meta-analysis compared endoscopic ultrasound-guided hepaticogastrostomy (EUS-HGS) using plastic versus metallic stents for malignant biliary obstruction after failed ERCP by pooling results from studies identified via PubMed/Medline/Web of Science. The analysis evaluated comparative outcomes including time to recurrent biliary obstruction (TRBO), clinical success, and adverse event rates. The findings are clinically significant because they help standardize stent selection for EUS-HGS in patients with malignant biliary obstruction.

Yamazaki H, Itonaga M, Wan K et al. · Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society · (2026) · View on PubMed ↗

VI Spanish Consensus Conference on the treatment of Helicobacter pylori infection.

This Spanish consensus conference article reviewed and synthesized evidence to produce updated recommendations for treating Helicobacter pylori infection in Spain. Using a systematic literature search and expert iterative voting, the panel developed 25 treatment recommendations reflecting changes in regimens and emerging evidence. The guidance is clinically significant because it standardizes H. pylori management for a high-prevalence population and supports evidence-based decision-making.

Gisbert JP, Alcedo J, Amador J et al. · Revista espanola de enfermedades digestivas · (2026) · View on PubMed ↗

---

Respiratory disease (including pulmonary fibrosis and pulmonary hypertension)

Pulse versus Nonpulse Corticosteroid Therapy in Acute Exacerbation of Idiopathic Pulmonary Fibrosis: A Multicenter, Randomized Clinical Trial (SAFER).

This multicenter, randomized clinical trial (SAFER) studied adults with acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) comparing intravenous pulse methylprednisolone (10 mg/kg for 3 days) versus a nonpulse regimen (1 mg/kg for 7 days) followed by protocolized tapering. The key finding was the trial’s test of whether pulse-dose corticosteroids improve short-term survival compared with the nonpulse regimen, addressing a guideline gap where dose and duration were previously weakly specified. If pulse therapy proves superior, it would directly inform corticosteroid dosing strategy for AE-IPF, potentially improving short-term mortality outcomes.

Kim H, Jang HJ, Kim SY et al. · American journal of respiratory and critical care medicine · (2026) · View on PubMed ↗

Pulmonary hypertension in anti-synthetase syndrome: prevalence, comparative risk across autoimmune diseases, and impact on survival.

The study analyzed a worldwide, physician-reported multicenter registry to determine the prevalence of pulmonary hypertension (PH) in anti-synthetase syndrome (ASyS), compare PH risk across autoimmune diseases, and assess impact on survival. The key finding is that PH occurs in real-world ASyS populations at a measurable prevalence and is associated with worse survival, with comparative analyses quantifying PH odds relative to other autoimmune disease groups. This is significant because it supports routine PH risk assessment in ASyS and highlights PH as a prognostic factor affecting patient outcomes.

Bae SS, Rivero Gallegos D, Bozan F et al. · Rheumatology (Oxford, England) · (2026) · View on PubMed ↗ · Free PDF ↗

Updated European Respiratory Society-American Thoracic Society (ERS-ATS) Classification of Interstitial Pneumonias: The Radiologic Perspective.

This radiology-focused review summarized the 2025 update to the European Respiratory Society–American Thoracic Society (ERS-ATS) classification of interstitial pneumonias, emphasizing revised terminology, pattern definitions, and a radiologic-pathologic pattern-based framework. It identifies three major interstitial patterns—usual interstitial pneumonia, nonspecific interstitial pneumonia, and bronchiolocentric interstitial pneumonia—explicitly broadening beyond idiopathic interstitial pneumonias to include secondary causes. The clinical significance is improved radiologic consistency for diagnosing and communicating interstitial pneumonia phenotypes that can guide downstream clinical-pathologic correlation and treatment planning.

Piciucchi S, Ryerson CJ, Johkoh T et al. · Radiology · (2026) · View on PubMed ↗

Real-world analysis on hemodynamic effectiveness and adverse events of selexipag in pulmonary arterial hypertension.

This retrospective observational real-world study in a Japanese cohort evaluated hemodynamic effectiveness and adverse events of selexipag, an oral IP prostacyclin receptor agonist, in pulmonary arterial hypertension (PAH). The key finding was an assessment of whether treatment-emergent adverse events—especially headache and diarrhea—were associated with subsequent hemodynamic responses, alongside overall efficacy and safety in routine practice (truncated). This is significant for clinicians because it may help interpret common AEs as potential markers of treatment response and improve tolerability management in PAH.

Asano R, Kiko T, Kawabata T et al. · Therapeutic advances in respiratory disease · (2026) · View on PubMed ↗ · Free PDF ↗

Integrated single-cell TCR analysis across tissue identifies GZMK+CD8+ T cells promoting fibrosis via TGF-β signalling in IPF.

This study used paired single-cell RNA sequencing and single-cell TCR profiling across lung, mediastinal lymph nodes, and peripheral blood from patients with severe idiopathic pulmonary fibrosis (IPF) to identify cross-tissue T cell populations. It found a GZMK+ CD8+ T cell subset enriched in fibrotic lung with an inflammatory, low-cytotoxic phenotype and a clonally related CD8_HSPA1A population enriched in lymph nodes, with higher GZMK+ CD8+ signatures linked to worse survival and impaired lung function. The work is significant because it defines a specific clonal CD8+ T cell program driven by TGF-β signaling that may contribute to fibrosis and could be targeted to modify disease progression.

Yue B, Jing S, Li Q et al. · International journal of biological sciences · (2026) · View on PubMed ↗ · Free PDF ↗

---

Genetics, epigenetics, and biomarkers (non-cancer)

PABPN1 pathogenic expansion in the UK Biobank: reframing genetic prevalence of oculopharyngeal muscular dystrophy.

This study assessed the prevalence and genetic framing of PABPN1 pathogenic GCN repeat expansions in the UK Biobank to better estimate oculopharyngeal muscular dystrophy (OPMD) risk across populations. The authors reported that PABPN1 expansion prevalence in the cohort can be reinterpreted in light of dosage effects, incomplete dominance, expression variability, and reduced penetrance for heterozygous carriers. This work improves genetic epidemiology for OPMD by refining how PABPN1 repeat expansions translate into expected clinical burden.

Villella C, Gagliardi D, Sebastiani E et al. · Journal of neurology, neurosurgery, and psychiatry · (2026) · View on PubMed ↗

Maternal and Child Health Status among Women Attending an Antenatal Clinic in a Tertiary Care Hospital of Bangladesh.

This cross-sectional survey studied maternal and child health status among 460 women attending an antenatal clinic at Mymensingh Medical College Hospital in Bangladesh (September–October 2025). The key finding was a quantified snapshot of sociodemographic factors, antenatal visit patterns, child-care practices, and delivery-related outcomes in this tertiary-care antenatal population. This is clinically significant because it highlights gaps in antenatal care and child health practices that can guide targeted interventions in Bangladesh.

Khan MK, Hossain SB, Nabil MJI et al. · Mymensingh medical journal : MMJ · (2026) · View on PubMed ↗

Exposome-wide association study and predictive risk score for incident Alzheimer’s disease and related dementias.

This exposome-wide association study used Cox proportional hazards models and machine learning to identify environmental exposures associated with incident Alzheimer’s disease and related dementias (ADRD) and to build a predictive exposomic risk score. The key finding was that among 499,992 UK Biobank participants, 193 exposures across social, physical, chemical, lifestyle, and ecosystems domains were evaluated and an XGBoost-based model produced an exposomic risk score for ADRD risk. This is clinically significant because it moves toward precision prevention by integrating multi-domain environmental data into risk prediction.

Li C, Zhao C, Lan Y et al. · Alzheimer’s & dementia : the journal of the Alzheimer’s Association · (2026) · View on PubMed ↗ · Free PDF ↗

Epigenome-wide profiling identifies distinct DNA methylation architecture underlying ME/CFS and fibromyalgia symptom burden.

This cross-sectional epigenome-wide profiling study measured peripheral blood mononuclear cell DNA methylation using the Illumina platform in 188 women (healthy controls, ME/CFS, and fibromyalgia) to identify methylation architectures linked to diagnosis and symptom burden. Distinct DNA methylation axes were associated with ME/CFS versus fibromyalgia and with quantitative symptom dimensions. These results support peripheral epigenetic signatures as potential biomarkers for differentiating overlapping chronic fatigue and pain disorders and for stratifying symptom-driven clinical phenotypes.

Polli A, Hendrix J, Wyns A et al. · Journal of translational medicine · (2026) · View on PubMed ↗ · Free PDF ↗

Direct Pharmacological Activation of AMPK Extends Lifespan in Yeast, Worms and Flies.

The study tested direct pharmacological activation of AMPK using compound 991 in yeast (Schizosaccharomyces pombe), nematodes (Caenorhabditis elegans), fruit flies (Drosophila melanogaster), and mice. 991 extended lifespan in yeast, worms, and flies and induced a pro-longevity proteomic profile in mice. These findings support AMPK as a druggable, causative longevity target and provide a more specific alternative to indirect AMPK activators like metformin.

Dos Santos E, Blickling M, Leiper FC et al. · Aging cell · (2026) · View on PubMed ↗ · Free PDF ↗

The early RNA decay factor ZC3H18 directs first intron splicing.

This study investigated how the RNA decay factor ZC3H18 regulates first intron splicing in human cells, focusing on its interactions with splicing factors PRPF40A, PRP4K, and FNBP4 and its linkage to the cap-binding complex (CBC) via ARS2. Genome-wide disruption of the CBC–ARS2–ZC3H18 axis corrupted first intron splicing, and ZC3H18 promoted first intron splicing through these splicing factor interactions. These findings connect early RNA decay machinery (NEXT recruitment) to splicing control, clarifying a mechanistic role for ZC3H18 in coordinating gene expression at the first intron step.

Le Rest M, El Houda Benbahouche N, Kuhn CC et al. · Molecular cell · (2026) · View on PubMed ↗

HLA-DRB1*04:05 in Epstein-Barr virus-seronegative multiple sclerosis: a Japanese single-center study.

This Japanese single-center retrospective study assessed whether the HLA-DRB104:05 susceptibility allele is enriched in Epstein-Barr virus (EBV)-seronegative multiple sclerosis (MS) patients, while accounting for MOG antibody testing. Among 123 Japanese MS patients meeting the 2017 McDonald criteria, EBV-seronegative MS showed an association with HLA-DRB104:05, consistent with prior reports but clarified by excluding MOG antibody-associated disease. Clinically, this strengthens the genetic link between HLA-DRB1*04:05 and EBV-seronegative MS risk in Japan and improves diagnostic stratification in rare EBV-seronegative cases.

Tomizawa Y, Shimoda H, Takai I et al. · Multiple sclerosis and related disorders · (2026) · View on PubMed ↗

Physiopathology of PMOS from a Neuroendocrine Perspective.

This article reviewed the physiopathology of polyendocrine metabolic ovarian syndrome (PMOS) from a neuroendocrine perspective, focusing on hypothalamic-pituitary-gonadal axis dysregulation. It highlights increased GnRH pulsatility driven by altered activity of hypothalamic kisspeptin neurons, leading to excess LH, disrupted LH/FSH balance, ovarian androgen excess, and anovulation. The synthesis is clinically significant because it reframes PMOS as a neuroendocrine-metabolic disorder, guiding more targeted approaches to treatment and research.

Cotellessa L, Bongiovanni S, Giacobini P · Physiology (Bethesda, Md.) · (2026) · View on PubMed ↗

Spatiotemporal modeling of GPCR signaling: The role of endosomal dynamics and receptor recycling.

The study developed a generic spatiotemporal model of G protein-coupled receptor (GPCR) signaling in which receptor trafficking (internalization, endosomal sorting, and recycling) is explicitly integrated with signaling compartmentalization. The key finding is that endosomal dynamics and receptor recycling substantially reshape ligand-induced signaling kinetics and spatial localization, altering predicted cellular responses compared with models that assume signaling only at the cell surface. This provides a mechanistic framework for interpreting how intracellular trafficking controls GPCR signaling outcomes and can guide more accurate, testable GPCR signaling hypotheses.

Weckel C, Gourdon J, Darrigade L et al. · PLoS computational biology · (2026) · View on PubMed ↗ · Free PDF ↗

Elevated Plasmodium falciparum sexual conversion in HbAC and HbAS red blood cells in naturally infected malaria patients.

The study investigated whether host hemoglobin beta (HBB) mutant genotypes (HbAS and HbAC) affect Plasmodium falciparum sexual conversion (SC) and humoral immunity in naturally infected individuals from Nanoro, Burkina Faso, using a newly developed ex vivo SC assay (evSCA). The key finding is that SC rates were elevated in infections from individuals with HbAS or HbAC compared with wild-type HbA, indicating that these HBB variants promote parasite commitment to gametocytogenesis. This is significant for understanding how human genetic variation influences malaria transmission potential and could inform risk stratification and intervention strategies.

Drissi-El Boukili Y, Kühne V, Natama HM et al. · PLoS pathogens · (2026) · View on PubMed ↗ · Free PDF ↗

The Ca2+ channel CYCLIC NUCLEOTIDE GATED CHANNEL13 regulates vasculature-mediated systemic Ca2+ and jasmonate signaling on herbivory.

The study identified and characterized the plant plasma-membrane Ca2+ channel CYCLIC NUCLEOTIDE GATED CHANNEL13 (CNGC13) in the context of vasculature-mediated systemic Ca2+ and jasmonate signaling during herbivory. The key finding is that CNGC13 is vasculature-expressed and regulates systemic Ca2+ signaling and downstream jasmonate-mediated defense responses, helping explain why long-distance Ca2+ signaling is not fully captured by glutamate receptor-like channel-centric models. This is significant because it defines a specific Ca2+ channel component that contributes to robust systemic plant immunity to diverse damage cues.

Kumari M, Prajapati R, Pawar M et al. · Proceedings of the National Academy of Sciences of the United States of America · (2026) · View on PubMed ↗ · Free PDF ↗

PKD2-like proteins target Chlamydomonas PKD2 to distinct subciliary regions.

The study used genome editing and in vivo imaging to determine how Chlamydomonas PKD2 is targeted to distinct subciliary regions, focusing on the PKD2-like protein MST3 (a 5-transmembrane-helix protein). The key finding is that MST3 localizes exclusively to the distal cilium and is essential for MST3-dependent localization of PKD2 and for hair-like mastigoneme formation, while MST3 is dispensable for PKD2 assembly. This clarifies how ciliary subdomain targeting mechanisms organize membrane proteins to specific functional regions, informing general principles of ciliary patterning.

Das P, Zhou H, Sureshkumar S et al. · Proceedings of the National Academy of Sciences of the United States of America · (2026) · View on PubMed ↗ · Free PDF ↗

Moving beyond 5-HT2A: language models map neurotransmitter receptors to experiential semantics.

This proof-of-concept study used a custom Global Vectors for Word Representation (GloVe)-based semantic embedding model trained on 4,496 firsthand psychedelic experience reports and integrated it with receptor binding profiles for 19 neurotransmitter receptors and 21 psychedelic drugs. The key finding was that language-model-derived semantic patterns can be mapped to receptor-linked associations, moving beyond the previously emphasized 5-HT2A receptor to identify candidate receptor-linked experiential effects. Scientifically, this provides a computational framework to prioritize receptor targets for psychedelic mechanism-of-action and potentially improve clinical translation by linking receptor pharmacology to subjective symptom dimensions.

Suresh P, Kins J, Levkovskyy L et al. · Psychopharmacology · (2026) · View on PubMed ↗

Epigenome-Wide Association Study of Abdominal Aortic Aneurysm Identifies Central Role for Inflammatory Pathways.

This study used an epigenome-wide association study (EWAS) in the VA Million Veteran Program to identify DNA methylation biomarkers associated with incident abdominal aortic aneurysm (AAA), followed by Mendelian randomization for causal inference. The key finding was that methylation signals implicate a central role for inflammatory pathways in AAA susceptibility, supported by stratified analyses by population group and smoking status and causal CpG-AAA inference. Scientifically, it advances mechanistic understanding of AAA and highlights candidate methylation targets for translational biomarker development.

Yuan S, Clark MG, Shakt G et al. · Circulation · (2026) · View on PubMed ↗ · Free PDF ↗

Differential Sperm DNA Methylation Profiles in Healthy Men With High Versus Low Adherence to the Mediterranean Diet in the Led-Fertyl Study.

This cross-sectional study examined whether adherence to the Mediterranean diet (MedDiet) is associated with sperm DNA methylation profiles in healthy men, stratifying 60 participants into high versus low MedDiet adherence groups. It assessed differential sperm DNA methylation patterns as the epigenetic readout linked to dietary adherence. The findings are significant because they suggest diet-related modulation of the sperm epigenome may contribute to downstream reproductive and offspring health effects.

Agarwal R, Babio N, Davila-Cordova E et al. · Andrology · (2026) · View on PubMed ↗ · Free PDF ↗

---

---

Generated automatically on October 01, 2026 from PubMed’s trending articles. Summaries are AI-generated; always consult the original publication for clinical or research decisions.